| |
 |
Jackie Fairley, BSc, BVSc (Hons), MBA
Chief Executive Officer
Dr Fairley was appointed Chief Executive Officer of Starpharma on 1 July 2006 after serving in the role of Chief Operating Officer from July 2005. As CEO and a Director of the Board, Jackie’s responsibilities include involvement in setting strategic direction, oversight of operations and financing activities for the group. She also plays an active role in driving key commercial negotiations and development programs and corporate activity. Jackie has more than 20 years’ experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Hospira). Former CEO of Cerylid Biosciences, Jackie also spent 5 years as Vice President for Faulding’s injectable division and 5 years with CSL in various executive roles. She holds first class honours degrees in Science (pharmacology/pathology) and Veterinary Science, and has an MBA from the Melbourne Business School where she was the recipient of the Clemenger Medal. |
 |
Paul Barett, BSc (Hons), PhD
Vice President, Business Development
Dr Barrett is responsible for the commercialisation of Starpharma’s dendrimer technology into pharmaceutical and related fields. Since he joined Starpharma in 2005 the Company has signed a series of partnering and commercialisation agreements including a licence with a potential value of more than $100m with SSL International for condom coating applications of VivaGel®, a wide ranging development and licencing agreement with Eli Lilly’s Animal Health division Elanco, and a number of other collaborations in areas including drug delivery and in vitro diagnostics. Prior to joining Starpharma he held positions at Nortel Networks, Smiths Industries Aerospace, the University of Oxford and Bookham Technology. Dr Barrett is a co-author on 13 publications in both the physical and biological sciences. |
 |
David Owen, BSc (Hons), PhD
Vice President, Research
Dr Owen has extensive experience in medicinal chemistry and biochemistry, and in managing teams focused on commercially directed drug discovery. He has held several positions in the biotech industry, starting with Mimotopes (part of Mitokor Inc.) as a senior chemist, and has worked on projects for several major pharmaceutical companies. He was head of chemistry at Cerylid Biosciences, and later Glykoz, where he headed a team of chemists working on a new class of antibacterial agents. Dr Owen has expertise in many areas of chemistry, including the synthesis of natural products, peptides, carbohydrates and heterocyclic compounds, and has worked across therapeutic areas including type 2 diabetes, antimicrobials and anticancer agents. He is a co-author on 20 publications and 5 patents. |
 |
Jeremy Paull, BSc (Hons), PhD
Vice President, Development and Regulatory Affairs
Dr Paull heads up Starpharma’s preclinical and clinical development programs and manages the Company’s interactions with international regulatory authorities. Jeremy also leads Starpharma’s NIH -funded programs, and is responsible for successful collaborations with the Company’s many international research and commercial development partners. Key priorities include the advancement of the VivaGel® standalone product through late-stage development, and the development of the coated condom product. Since joining Starpharma in 2001, Dr Paull’s efforts have been integral to the advancement of the VivaGel® development program. |
 |
Nigel Baade, BCom , CPA, Grad Dip Arts (Development)
Chief Financial Officer
Mr Baade is a CPA -qualified accountant with extensive experience in the pharmaceutical and biotechnology industries. Appointed to the position on 1 January 2009, he is responsible for the financial control and compliance of the Group. Mr Baade has experience in project and cost management of research activities, commercialisation of global business development opportunities, public and private equity raising and grant funding compliance. Prior to joining Starpharma as Financial Controller in 2006, he has held positions at Hagemeyer, Cerylid Biosciences, Faulding (Hospira) and UMT (Fonterra). He holds qualifications from University of Tasmania and Monash University. |
 |
Ben Rogers
Company Secretary
As Company Secretary Mr Rogers is the chief administrative officer of the Company and has the principal role of supporting the work of the Board. He has extensive experience in finance, corporate governance and HR management with CSIRO research laboratories and Co-operative Research Centres in Victoria, South Australia and Western Australia. Mr Rogers was a member of Starpharma’s start-up/IPO management team and has been Company Secretary since February 1998. Until 31 December 2008 his responsibilities also included the role of Chief Financial Officer. |
|  |
|
